 <h1>Axitinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of axitinib include:</b> headache, hypertension, hypothyroidism, increased serum alanine aminotransferase, and proteinuria.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to axitinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, axitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking axitinib:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bloody nose</li>
<li>blurred vision</li>
<li>clay colored stools</li>
<li>cloudy urine</li>
<li>confusion</li>
<li>constipation</li>
<li>coughing up blood</li>
<li>decreased urination</li>
<li>depressed mood</li>
<li>difficult or labored breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>dry skin and hair</li>
<li>fainting</li>
<li>feeling cold</li>
<li>fever</li>
<li>hair loss</li>
<li>headache</li>
<li>hoarseness or husky voice</li>
<li>incoherent speech</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>increased urination</li>
<li>itching skin or rash</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>metallic taste</li>
<li>muscle cramps, stiffness, or weakness</li>
<li>nausea</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>pounding in the ears</li>
<li>rapid breathing</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>slow or fast heartbeat</li>
<li>stomach pain or tenderness</li>
<li>sunken eyes</li>
<li>swelling of the feet or lower legs</li>
<li>thirst</li>
<li>tightness in the chest</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weight gain or loss</li>
<li>wrinkled skin</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>bleeding from the gums or nose</li>
<li>bleeding from the rectum</li>
<li>bloody, black or tarry stools</li>
<li>change in vision</li>
<li>chest pain or discomfort</li>
<li>extreme drowsiness</li>
<li>eye pain</li>
<li>heartburn</li>
<li>inability to speak</li>
<li>indigestion</li>
<li>numbness or tingling in the face, arms, hands, or legs</li>
<li>pain in the chest, groin, or legs</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>pale skin</li>
<li>ringing in the ears</li>
<li>seizures</li>
<li>sensitivity to heat</li>
<li>severe headaches of sudden onset</li>
<li>severe stomach pain, cramping, or burning</li>
<li>slurred speech</li>
<li>sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>sudden loss of coordination</li>
<li>sudden onset of slurred speech</li>
<li>sudden vision changes</li>
<li>sweating</li>
<li>temporary blindness</li>
<li>trouble sleeping</li>
<li>trouble speaking, thinking, or walking</li>
<li>troubled breathing with exertion</li>
<li>uncomfortable swelling around the anus</li>
<li>unusual bleeding or bruising</li>
<li>vomiting of material that looks like coffee grounds</li>
<li>weakness in the arm or leg on one side of the body</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of axitinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>change in taste</li>
<li>cough</li>
<li>cracked lips</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>joint pain or swelling</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>muscle aches or pain</li>
<li>pain in the arms or legs</li>
<li>sore throat</li>
<li>stomach discomfort or upset</li>
<li>swelling or inflammation of the mouth</li>
<li>upper stomach pain</li>
<li>voice changes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning sensation of the tongue</li>
<li>continuous ringing or buzzing or other unexplained noise in the ears</li>
<li>flushing or redness of the skin</li>
<li>hearing loss</li>
<li>thinning of the hair</li>
<li>unusually warm skin</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to axitinib: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions included diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, decreased weight, vomiting, asthenia, and constipation.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Hypertension has been reported in up to 40% or patients, with grade 3 or 4 hypertension and hypertensive crisis in 16% and less than 1% of those patients, respectively.  The median onset time for hypertension was within the first month, with increases observed as early as 4 days after starting the drug.  Less than 1% of patients discontinued therapy due to hypertension.  </p>
<p></p>
<p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715) and venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).</p>
<p></p>
<p>Cardiac failure was reported in 2% (6 of 359) patients; grade 3 or 4 in 1% (2 of 359).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (40%)</p>
<p><b>Common</b> (1% to 10%): Deep vein thrombosis, cardiac failure events, venous thromboembolic events, arterial thromboembolic events, myocardial infarction</p>
<p><b>Rare</b> (less than 0.1%): Hypertensive crisis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%), dysgeusia (11%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, transient ischemic attack</p>
<p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome</p>
<p><b>Frequency not reported</b>: Cerebrovascular accidents<sup>[Ref]</sup></p><p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715).  </p>
<p></p>
<p>Three cases of reversible posterior leukoencephalopathy syndrome (RPLS), also known as posterior reversible encephalopathy syndrome (PRES) were reported during clinical trials.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715).  Venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Retinal vein occlusion/thrombosis </p>
<p><b>Frequency not reported</b>: Retinal artery occlusions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (55%), nausea (32%), vomiting (24%), constipation (20%), stomatitis (15%), abdominal pain (14%), increased lipase (27%), increased amylase (25%) </p>
<p><b>Common</b> (1% to 10%): Upper abdominal pain, hemorrhoids, glossodynia, rectal hemorrhage, dyspepsia, flatulence</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal perforation, fistulas</p>
<p><b>Frequency not reported</b>: Lower gastrointestinal hemorrhage, melena<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminase increases (20% to 22%), alkaline phosphatase increases (30%), hypoalbuminemia (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (55%), proteinuria (11%)</p>
<p><b>Common</b> (1% to 10%): Hematuria, renal failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (39%), asthenia (21%), </p>
<p><b>Common</b> (1% to 10%): Tinnitus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hand-foot syndrome (27%), rash (13%) </p>
<p><b>Common</b> (1% to 10%): Pruritus, alopecia, erythema, dry skin<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Hypothyroidism was reported in 20.9% of patients and hyperthyroidism in 1.1%.  Among patients with TSH levels less than 5 micromoles/mL prior to treatment, elevations to greater 10 micromoles/mL occurred in greater than 32.2%<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypothyroidism (20%), </p>
<p><b>Common</b> (1% to 10%): Hyperthyroidism, increased thyroid stimulating hormone (TSH)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (35%), decreased lymphocytes (33%) decreased platelets (15%), WBC decreased (11%) </p>
<p><b>Common</b> (1% to 10%): Anemia, polycythemia, increased hemoglobin</p>
<p><b>Uncommon</b> (0.1% to 1%): Neutropenia, leukopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (34%), weight loss (25%), decreased bicarbonate (44%), hypocalcemia (39%), hyperglycemia (28%), hypernatremia (17%), hyperkalemia (15%), hypoglycemia (11%), hyponatremia (13%), hypophosphatemia (13%) </p>
<p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (15%), extremity pain (14%), </p>
<p><b>Common</b> (1% to 10%): Myalgia,<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dysphonia (31%), cough (15%), mucosal inflammation (15%), dyspnea (15%) </p>
<p><b>Common</b> (1% to 10%): Epistaxis, pulmonary embolism, hemoptysis<sup>[Ref]</sup></p><p>Venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Inlyta (axitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How are axitinib and pembrolizumab used in kidney cancer?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about axitinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Axitinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Inlyta</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Renal Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to axitinib: oral tablet</i></p><h3>General</h3><p>The most common adverse reactions included diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, decreased weight, vomiting, asthenia, and constipation.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Hypertension has been reported in up to 40% or patients, with grade 3 or 4 hypertension and hypertensive crisis in 16% and less than 1% of those patients, respectively.  The median onset time for hypertension was within the first month, with increases observed as early as 4 days after starting the drug.  Less than 1% of patients discontinued therapy due to hypertension.  </p><p></p><p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715) and venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).</p><p></p><p>Cardiac failure was reported in 2% (6 of 359) patients; grade 3 or 4 in 1% (2 of 359).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypertension (40%)</p><p><b>Common</b> (1% to 10%): Deep vein thrombosis, cardiac failure events, venous thromboembolic events, arterial thromboembolic events, myocardial infarction</p><p><b>Rare</b> (less than 0.1%): Hypertensive crisis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%), dysgeusia (11%)</p><p><b>Common</b> (1% to 10%): Dizziness, transient ischemic attack</p><p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome</p><p><b>Frequency not reported</b>: Cerebrovascular accidents<sup>[Ref]</sup></p><p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715).  </p><p></p><p>Three cases of reversible posterior leukoencephalopathy syndrome (RPLS), also known as posterior reversible encephalopathy syndrome (PRES) were reported during clinical trials.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Arterial thromboembolic events including transient ischemic attacks, cerebrovascular accidents, myocardial infarctions, and retinal artery occlusions were reported in 2% of patients (17 of 715).  Venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Retinal vein occlusion/thrombosis </p><p><b>Frequency not reported</b>: Retinal artery occlusions<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (55%), nausea (32%), vomiting (24%), constipation (20%), stomatitis (15%), abdominal pain (14%), increased lipase (27%), increased amylase (25%) </p><p><b>Common</b> (1% to 10%): Upper abdominal pain, hemorrhoids, glossodynia, rectal hemorrhage, dyspepsia, flatulence</p><p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal perforation, fistulas</p><p><b>Frequency not reported</b>: Lower gastrointestinal hemorrhage, melena<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminase increases (20% to 22%), alkaline phosphatase increases (30%), hypoalbuminemia (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (55%), proteinuria (11%)</p><p><b>Common</b> (1% to 10%): Hematuria, renal failure<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (39%), asthenia (21%), </p><p><b>Common</b> (1% to 10%): Tinnitus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hand-foot syndrome (27%), rash (13%) </p><p><b>Common</b> (1% to 10%): Pruritus, alopecia, erythema, dry skin<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Hypothyroidism was reported in 20.9% of patients and hyperthyroidism in 1.1%.  Among patients with TSH levels less than 5 micromoles/mL prior to treatment, elevations to greater 10 micromoles/mL occurred in greater than 32.2%<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Hypothyroidism (20%), </p><p><b>Common</b> (1% to 10%): Hyperthyroidism, increased thyroid stimulating hormone (TSH)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased hemoglobin (35%), decreased lymphocytes (33%) decreased platelets (15%), WBC decreased (11%) </p><p><b>Common</b> (1% to 10%): Anemia, polycythemia, increased hemoglobin</p><p><b>Uncommon</b> (0.1% to 1%): Neutropenia, leukopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (34%), weight loss (25%), decreased bicarbonate (44%), hypocalcemia (39%), hyperglycemia (28%), hypernatremia (17%), hyperkalemia (15%), hypoglycemia (11%), hyponatremia (13%), hypophosphatemia (13%) </p><p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (15%), extremity pain (14%), </p><p><b>Common</b> (1% to 10%): Myalgia,<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dysphonia (31%), cough (15%), mucosal inflammation (15%), dyspnea (15%) </p><p><b>Common</b> (1% to 10%): Epistaxis, pulmonary embolism, hemoptysis<sup>[Ref]</sup></p><p>Venous thromboembolic events including pulmonary embolism, deep vein thrombosis, retinal vein occlusion, and retinal vein thrombosis were reported in 3% of patients (22 of 715).<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Inlyta (axitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How are axitinib and pembrolizumab used in kidney cancer?</li>
</ul><h2>More about axitinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Axitinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Renal Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>